Arnon Nagler, MD, Sheba Medical Center, Tel-Aviv, Israel, discusses the exciting field of immunotherapy in relapsed refractory (R/R) acute lymphoblastic leukemia (ALL). Two monoclonal antibodies; blinatumomab, and inotuzumab are now available for ALL as well as CAR T-cell therapy for patients up to the age of 25 years. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.